Special Issue "New Insights on Canine Visceral Leishmaniasis"
Deadline for manuscript submissions: closed (1 December 2023) | Viewed by 3304
Interests: leishmaniasis; vaccine; immunology; diagnosis
Special Issues, Collections and Topics in MDPI journals
Special Issue in Pathogens: Neglected and Emergent Diseases
Interests: bioinformatics, cloning and expression of heterologous proteins; optimization of recombinant protein production; immunoenzymatic assays; maintenance of experimental animals, including mice, hamsters and dogs; development of products and processes for vaccines against diseases of medical and veterinary interest
Leishmaniasis is a group of infectious and parasitic diseases caused by protozoa of the genus Leishmania. Leishmaniasis manifests a wide clinical spectrum, and among them, visceral leishmaniasis (VL) is the most severe form. VL caused by Leishmania infantum (sin. Leishmania chagasi) is a zoonosis whose main urban reservoir is the dog (Canis familiaris). Importantly, cases of canine visceral leishmaniasis (CVL) precede HVL cases, emphasizing the important role of dogs in the urban parasite transmission cycle.
Diagnostic method improvements are required in addition to immunoprophylactic approaches that is the main rational strategy to control the human and canine VL. Moreover, additional challenges are the new treatments and predictive disease biomarker studies regarding the CVL resistance and susceptibility outcome.
We invite investigators to contribute original research articles as well as review articles that will stimulate the continuing efforts to advance in the field of diagnosis, immunopathologic, treatment, and vaccine approaches against CVL.
Potential topics include but are not limited to:
- Development and testing of novel and effective anti-VL vaccines;
- Identification of antigenic targets for both diagnosis and vaccine approaches;
- Analysis of new adjuvants and antigenic formulations able to enhance the immunogenicity and efficacy;
- Identifying biomarkers/correlates of protective immunity against VL;
- New methodologies useful to perform the selection and/or testing of vaccine candidates using in vitro, preclinical, and clinical trial platforms;
- High-performance methodologies to screening field samples, including new methodologies able to more accurately induce the diagnosis of VL;
- Development and testing of new immunobiologicals to act as immunotherapy;
- Studies focusing on the interaction of parasite and sandfly vectors of Leishmania
Before submission, authors should carefully read over the journal’s Author Guidelines, which are located at: https://www.mdpi.com/journal/pathogens/instructions.
Dr. Rodolfo Cordeiro Giunchetti
Dr. Reysla Maria da Silveira Mariano
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.